binance left Coinmarketcap net_left adver left
Detail

Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments

By Ankur Banerjee and Amruta Khandekar (Reuters) - The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm...
Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments © Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder

By Ankur Banerjee and Amruta Khandekar

(Reuters) - The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.

In a draft decision on Tuesday, the Centers for Medicaid and Medicare Services (CMS), which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials.

Shares of Biogen Inc (NASDAQ:BIIB) were down more than 7% at $223.77 in afternoon trading, while shares of drugmakers developing similar treatments such as Eli Lilly (NYSE:LLY) and Co, Roche Holding AG (OTC:RHHVF) and Eisai Co (OTC:ESALY) Ltd fell between 2% and 5%.

"It would appear that what is occurring is that cost is being put before the needs of Alzheimer's patients," Harry Johns, chief executive at the Alzheimer's Association patient advocacy group, told Reuters.

He estimated that out of the one million or so Alzheimer's patients who might now be eligible for Aduhelm, a few thousand at best could be enrolled in future CMS-approved trials, which will take years to conduct.

Aduhelm's high price has raised concerns over the toll it might take on the Medicare program since Alzheimer's is an age-related disease and around 85% of people who might use the drug are in the government plan.

Other health insurers have also questioned whether Aduhelm's benefits are worth the cost.

"We agree with CMS there is a need to obtain more clinical data on efficacy, which will be essential to ensuring these new medications deliver real value to patients before broadening access," Matt Eyles, president and CEO of trade group America's Health Insurance Plans, said.

Sales so far have been weak and Biogen last month cut the medication's list price by about half to $28,200 per year.

Biogen had been banking on the government's coverage decision to help drive sales of Aduhelm, which was approved by the U.S. Food and Drug Administration in June, despite a vote by the agency's outside advisers that the treatment's clinical benefits had not been proven.

Only one of Biogen's two pivotal trials showed Aduhelm can slow the rate of cognitive decline for Alzheimer's patients.

Medicare's draft decision essentially crushes any hopes of Aduhelm gaining traction any time soon, J.P. Morgan analyst Cory Kasimov said.

Analysts said the decision, if left in place, could result in negligible Aduhelm sales in 2022 and 2023. The treatment brought in sales of $300,000 in the third quarter, compared with the average analyst estimate of $10.8 million.

"It is imperative to change this draft decision to be aligned with reimbursement for other therapies for progressive diseases, where patients have immediate and equal access to medicines approved by the FDA," Biogen said in a statement.

Aduhelm, given as a monthly infusion, is a monoclonal antibody designed to remove a type of brain plaque associated with Alzheimer's Disease. Patients need to be monitored for potential side effects including brain swelling.

The agency's final coverage terms, due by April 12, are expected to apply to all drugs in the class.

Eli Lilly is conducting a head-to-head study comparing its experimental drug donanemab to Aduhelm and suggested it would not face similar restrictions if it demonstrates clear benefit.

"We expect that for drugs with established efficacy CMS will ensure access for all appropriate patients without creating further health inequities," Lilly said in an emailed statement.

ig right nyse right Neteller adver right
APPROVED BROKERS
rakuten_main right top net_home_top ig_main right top Binance _ main right top fbs_main right top tifia_main right top
26-01-2022 08:43:59 (UTC+7)

EUR/USD

1.1278

-0.0022 (-0.19%)

Summary

Neutral

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (5)

Sell (4)

EUR/USD

1.1278

-0.0022 (-0.19%)

Summary

Neutral

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (5)

Sell (4)

GBP/USD

1.3510

+0.0014 (+0.10%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (5)

Sell (2)

USD/JPY

114.26

+0.41 (+0.36%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (2)

Sell (6)

AUD/USD

0.7172

+0.0024 (+0.34%)

Summary

Buy

Moving Avg:

Buy (7)

Sell (5)

Indicators:

Buy (4)

Sell (3)

USD/CAD

1.2576

-0.0052 (-0.41%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (2)

EUR/JPY

128.87

+0.22 (+0.17%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (4)

Sell (3)

EUR/CHF

1.0386

+0.0011 (+0.11%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

Gold Futures

1,846.15

-6.35 (-0.34%)

Summary

Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (4)

Sell (4)

Silver Futures

23.983

+0.087 (+0.36%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (6)

Sell (1)

Copper Futures

4.5210

+0.0710 (+1.60%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (6)

Crude Oil WTI Futures

86.90

+1.30 (+1.52%)

Summary

Neutral

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (3)

Sell (4)

Brent Oil Futures

88.53

+1.35 (+1.55%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (5)

Sell (3)

Natural Gas Futures

4.181

+0.287 (+7.37%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (10)

Sell (0)

US Coffee C Futures

240.10

+2.20 (+0.92%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (1)

Sell (7)

Euro Stoxx 50

4,180.95

+102.69 (+2.52%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (0)

Sell (9)

S&P 500

4,356.45

-53.68 (-1.22%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (10)

DAX

15,501.99

+378.12 (+2.50%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (1)

Sell (6)

FTSE 100

7,511.85

+140.39 (+1.90%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (0)

Sell (8)

Hang Seng

24,289.90

+46.29 (+0.19%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

US Small Cap 2000

2,004.80

-28.71 (-1.41%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (2)

Sell (8)

IBEX 35

8,664.49

+184.99 (+2.18%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (10)

BASF SE NA O.N.

67.775

+2.445 (+3.74%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (0)

Sell (6)

Bayer AG NA

51.74

+0.92 (+1.81%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (7)

Allianz SE VNA O.N.

224.78

+4.73 (+2.15%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (6)

Adidas AG

246.43

+8.68 (+3.65%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (7)

Deutsche Lufthansa AG

7.069

+0.392 (+5.87%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (1)

Sell (8)

Siemens AG Class N

142.47

+3.95 (+2.85%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (6)

Deutsche Bank AG

11.464

+0.390 (+3.52%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (1)

Sell (9)

 EUR/USD1.1278Neutral
 GBP/USD1.3510Neutral
 USD/JPY114.26Sell
 AUD/USD0.7172Buy
 USD/CAD1.2576↑ Buy
 EUR/JPY128.87Buy
 EUR/CHF1.0386↑ Buy
 Gold1,846.15Buy
 Silver23.983↑ Buy
 Copper4.5210Sell
 Crude Oil WTI86.90Neutral
 Brent Oil88.53↑ Buy
 Natural Gas4.181↑ Buy
 US Coffee C240.10↑ Sell
 Euro Stoxx 504,180.95Sell
 S&P 5004,356.45↑ Sell
 DAX15,501.99Neutral
 FTSE 1007,511.85Neutral
 Hang Seng24,289.90↑ Buy
 Small Cap 20002,004.80↑ Sell
 IBEX 358,664.49↑ Sell
 BASF67.775Sell
 Bayer51.74↑ Sell
 Allianz224.78↑ Sell
 Adidas246.43Sell
 Lufthansa7.069↑ Sell
 Siemens AG142.47Sell
 Deutsche Bank AG11.464↑ Sell
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,190/ 6,240
(-5/ -5) # 1,175
SJC HCM6,180/ 6,245
(-10/ -10) # 1,179
SJC Hanoi6,180/ 6,247
(-10/ -10) # 1,181
SJC Danang6,180/ 6,247
(-10/ -10) # 1,181
SJC Nhatrang6,180/ 6,247
(-10/ -10) # 1,181
SJC Cantho6,180/ 6,247
(-10/ -10) # 1,181
Cập nhật 26-01-2022 08:44:01
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,846.30-3.44-0.19%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩmVùng 1Vùng 2
RON 95-IV2486025350
RON 95-II,III
E5 RON 92-II2359024060
DO 0.05S1890019270
DO 0,001S-V1925019630
Dầu hỏa1779018140
ↂ Giá dầu thô thế giới
WTI$86.47-1.5-1.77%
Brent$88.52-1.52-1.75%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD22.460,0022.770,00
EUR24.918,8126.315,80
GBP29.789,2431.061,45
JPY192,82204,12
KRW16,3519,92
Cập nhật lúc 18:54:49 26/01/2022
Xem bảng tỷ giá hối đoái
binance main right Fxpro Main Right aetos main right adver main right